Evidence map›Paper›PMID 34610317›Full record

ArticleCell reports2021

Attenuation of apoptotic cell detection triggers thymic regeneration after damage.

Sinéad Kinsella, Cindy A Evandy, Kirsten Cooper, Lorenzo Iovino, Paul C deRoos, Kayla S Hopwo, David W Granadier, Colton W Smith, Shahin Rafii, Jarrod A Dudakov

Open access · goldAbstract read
In one paragraph

Article in Cell reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Resolving the field: a role for Nod2 in T cells.Journal of immunology (Baltimore, Md. : 1950) · 2025
    Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Sinéad KinsellaProgram in Immunology, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA. Electronic address: skinsell@fredhutch.org.
Cindy A EvandyProgram in Immunology, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Kirsten CooperProgram in Immunology, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Lorenzo IovinoProgram in Immunology, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Paul C deRoosProgram in Immunology, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Kayla S HopwoProgram in Immunology, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
David W GranadierProgram in Immunology, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Colton W SmithProgram in Immunology, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Shahin RafiiDepartment of Genetic Medicine and Ansary Stem Cell Institute, Weill Cornell Medical College, New York, NY 10021, USA.
Jarrod A DudakovProgram in Immunology, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; Immunotherapy Integrated Research Center, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; Department of Immunology, University of Washington, Seattle, WA 98109, USA. Electronic address: jdudakov@fredhutch.org.
Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa · ZACornell University · USUniversity of Washington · US

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
Thymic and Peripheral Aspects of T Cell Aging and RejuvenationP01AG052359 · NIA · UNIVERSITY OF ARIZONA · PI JANKO Z. NIKOLICH · 2017 to 2026
$23.5M
Stem Cell and Transplantation BiologyU54DK106829 · NIDDK · FRED HUTCHINSON CANCER RESEARCH CENTER · PI DEREK L STIREWALT · 2015 to 2026
$9.1M
Modulation of signaling from damage-associated molecular patterns to improve radiation-induced thymic dysfunctionU01AI170035 · NIAID · FRED HUTCHINSON CANCER CENTER · PI Jarrod Dudakov · 2022 to 2026
$3.0M
Harnessing endogenous mechanisms of thymic regeneration toboost immune function in recipients of hematopoietic cell transplantR01HL145276 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI DUDAKOV, JARROD · 2019 to 2023
$2.8M
Regulation of thymic regeneration by GPR39R01HL165673 · NHLBI · FRED HUTCHINSON CANCER CENTER · PI DUDAKOV, JARROD · 2022 to 2023
$1.2M
Investigating the role of interleukin-22 in thymus functionR00CA176376 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI DUDAKOV, JARROD · 2016 to 2018
$741k
NCI NIH HHS P30 CA015704NCI NIH HHS R00 CA176376NHLBI NIH HHS R01 HL145276NHLBI NIH HHS R01 HL165673NIAID NIH HHS U01 AI170035NIA NIH HHS P01 AG052359NIDDK NIH HHS U54 DK106829
6 · The paper itself

Abstract

The thymus, which is the primary site of T cell development, is particularly sensitive to insult but also has a remarkable capacity for repair. However, the mechanisms orchestrating regeneration are poorly understood, and delayed repair is common after cytoreductive therapies. Here, we demonstrate a trigger of thymic regeneration, centered on detecting the loss of dying thymocytes that are abundant during steady-state T cell development. Specifically, apoptotic thymocytes suppressed production of the regenerative factors IL-23 and BMP4 via TAM receptor signaling and activation of the Rho-GTPase Rac1, the intracellular pattern recognition receptor NOD2, and micro-RNA-29c. However, after damage, when profound thymocyte depletion occurs, this TAM-Rac1-NOD2-miR29c pathway is attenuated, increasing production of IL-23 and BMP4. Notably, pharmacological inhibition of Rac1-GTPase enhanced thymic function after acute damage. These findings identify a complex trigger of tissue regeneration and offer a regenerative strategy for restoring immune competence in patients whose thymic function has been compromised.

Indexed as

ApoptosisRegenerationAnimalsBone Morphogenetic Protein 4FemaleInterleukin-23MaleMiceMice, Inbred C57BLMicroRNAsNod2 Signaling Adaptor ProteinPhosphatidylserinesPyronesQuinolinesrac1 GTP-Binding ProteinThymocytesBone Morphogenetic Protein 4EHT 1864Interleukin-23MicroRNAsMIRN29 microRNA, mouseNod2 protein, mouseNod2 Signaling Adaptor ProteinPhosphatidylserinesPyronesQuinolinesrac1 GTP-Binding Proteinapoptotic cell deathlymphopeniaNOD2Rac1 GTPaseTAM receptorsT cell developmentthymustissue regeneration

Identifiers

PMID34610317
PMCPMC8627669
OpenAlexW3203498823

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.